You are here: Home / Archives for Videos / Disease Videos

Link Between Omega-3 Fatty Acids and Increased Prostate Cancer Risk Confirmed

July 15, 2013 By Leave a Comment

Consumption of fatty fish and fish-oil supplements linked to 71 percent higher risk: 

Alan Kristal

Senior author Alan Kristal, Dr.P.H., is a member of the Public Health Sciences Division at Fred Hutch.

A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer.

Published in the online edition of the Journal of the National Cancer Institute, the latest findings indicate that high concentrations of EPA, DPA and DHA – the three anti-inflammatory and metabolically related fatty acids derived from fatty fish and fish-oil supplements – are associated with a 71 percent increased risk of high-grade prostate cancer. The study also found a 44 percent increase in the risk of low-grade prostate cancer and an overall 43 percent increase in risk for all prostate cancers.

The increase in risk for high-grade prostate cancer is important because those tumors are more likely to be fatal.

The findings confirm a 2011 study published by the same Fred Hutch scientific team that reported a similar link between high blood concentrations of DHA and a more than doubling of the risk for developing high-grade prostate cancer. The latest study also confirms results from a large European study.

“The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis and recommendations to increase long-chain omega-3 fatty acid intake, in particular through supplementation, should consider its potential risks,” the authors wrote.

“We’ve shown once again that use of nutritional supplements may be harmful,” said Alan Kristal, Dr.P.H., the paper’s senior author and member of the Fred Hutch Public Health Sciences Division. Kristal also noted a recent analysis published in the Journal of the American Medical Association that questioned the benefit of omega-3 supplementation for cardiovascular diseases. The analysis, which combined the data from 20 studies, found no reduction in all-cause mortality, heart attacks or strokes.

Theodore Brasky

Corresponding author Theodore Brasky, Ph.D., a research assistant professor at The Ohio State University Comprehensive Cancer Center, was a postdoctoral trainee at Fred Hutch when the research was conducted.

“What’s important is that we have been able to replicate our findings from 2011 and we have confirmed that marine omega-3 fatty acids play a role in prostate cancer occurrence,” said corresponding author Theodore Brasky, Ph.D., a research assistant professor at The Ohio State University Comprehensive Cancer Center who was a postdoctoral trainee at Fred Hutch when the research was conducted. “It’s important to note, however, that these results do not address the question of whether omega-3’s play a detrimental role in prostate cancer prognosis,” he said.

Kristal said the findings in both Fred Hutch studies were surprising because omega-3 fatty acids are believed to have a host of positive health effects based on their anti-inflammatory properties. Inflammation plays a role in the development and growth of many cancers.

It is unclear from this study why high levels of omega-3 fatty acids would increase prostate cancer risk, according to the authors, however the replication of this finding in two large studies indicates the need for further research into possible mechanisms. One potentially harmful effect of omega-3 fatty acids is their conversion into compounds that can cause damage to cells and DNA, and their role in immunosuppression. Whether these effects impact cancer risk is not known.

The difference in blood concentrations of omega-3 fatty acids between the lowest and highest risk groups was about 2.5 percentage points  (3.2 percent vs. 5.7 percent), which is somewhat larger than the effect of eating salmon twice a week, Kristal said.

The current study analyzed data and specimens collected from men who participated in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a large randomized, placebo-controlled trial to test whether selenium and vitamin E, either alone or combined, reduced prostate cancer risk. That study showed no benefit from selenium intake and an increase in prostate cancers in men who took vitamin E.

The group included in this analysis consisted of 834 men who had been diagnosed with incident, primary prostate cancers (156 were high-grade cancer) along with a comparison group of 1,393 men selected randomly from the 35,500 participants in SELECT.

The National Cancer Institute and the National Center for Complementary and Alternative Medicine funded the research.

Also participating in the study were additional Fred Hutch scientists and researchers from the University of Texas, University of California, University of Washington, National Cancer Institute and the Cleveland Clinic.

 Fish oil linked to prostate cancer. NBC’s Dr. Nancy Snyderman reports.

 

References

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. J Natl Cancer Inst 2013 Jul 10. [Epub ahead of print]

Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2011; 173: 1429-39.

Council for Responsible Nutrition. CRN Says New Study on Omega-3 Conclusions Are Overblown. Press Release, July 11, 2013.

 

Filed Under: Cancer, Cancer (videos), Nutrition (videos), Omega-3 Fatty Acids Tagged With: , , , , , ,

1-in-50 U.S. school kids has autism: Gov’t survey

March 21, 2013 By Leave a Comment

A government survey of parents says 1-in-50 U.S. schoolchildren has autism, surpassing earlier federal estimate for the disorder. Health officials say the new number doesn’t mean autism is occurring more often. But it does suggest that doctors are diagnosing autism more frequently, especially in children with milder problems. The earlier government estimate of 1-in-88 comes from a study that many consider more rigorous. It looks at medical and school records instead of relying on parents.

For decades, autism meant kids with severe language, intellectual and social impairments and unusual, repetitious behaviors. But the definition has gradually expanded and now includes milder, related conditions. The new report released on March 20, 2013 by the Centers for Disease Control and Prevention would mean at least 1 million children have autism. The number is important: Government officials look at how common each illness or disorder is when weighing how to spend limited public health funds. It’s also controversial.

The new statistic comes from a national phone survey of more than 95,000 parents in 2011 and 2012. Less than a quarter of the parents contacted agreed to answer questions, and it’s likely that those with autistic kids were more interested than other parents in participating in a survey on children’s health, CDC officials said. Still, CDC officials believe the survey provides a valid snapshot of how many families are affected by autism, said Stephen Blumberg, the CDC report’s lead author.

The study that came up with the 1-in-88 estimate had its own limitations. It focused on 14 states, only on children 8 years old, and the data came from 2008. Updated figures based on medical and school records are expected next year. “We’ve been underestimating” how common autism is, said Michael Rosanoff of Autism Speaks, an advocacy group. He believes the figure is at least 1-in-50.

There are no blood or biologic tests for autism, so diagnosis is not an exact science. It’s identified by making judgments about a child’s behavior. Physicians have been looking for autism at younger and younger ages, and experts have tended to believe most diagnoses are made in children by age 8. However, the new study found significant proportions of children were diagnosed at older ages.

Dr. Roula Choueiri, a neurodevelopmental pediatrician at Tufts Medical Center in Boston, said she’s seen that happening at her clinic. Those kids “tend to be the mild ones, who may have had some speech delays, some social difficulties,” she wrote in an email. But they have more problems as school becomes more demanding and social situations grow more complex, she added.

The greatest change in prevalence estimates was seen in boys and for adolescents aged 14 to 17 years old. Also, children who were first diagnosed in or after 2008 were more likely to have milder autism than those diagnosed in or before 2007, which may be because of increased awareness among parents and doctors and better diagnostic testing.

 

References 

Blumberg SJ, Bramlett MD, Kogan MD, Schieve LA, Jones JR. Changes in Prevalence of Parent-reported Autism Spectrum Disorder in School-aged U.S. Children: 2007 to 2011–2012. National Health Statistics Reports 2013; Number 65: 1-11.

Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders–Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ. 2012; 61 (3): 1-19.

 

 

Filed Under: Autism, Autism Tagged With:

Hofmann’s Potion

March 14, 2013 By Leave a Comment

This documentary offers a compassionate, open-minded look at LSD and how it fits into our world. Long before Timothy Leary urged a generation to “tune in, turn on and drop out,” the drug was hailed as a way to treat forms of addiction and mental illness. At the same time, it was being touted as a powerful tool for mental exploration and self-understanding.

Featuring interviews with LSD pioneers, beautiful music and stunning cinematography, this is much more than a simple chronicle of LSD’s early days. It’s an alternative way of looking at the drug… and our world. (National Film Board of Canada, 2002)

Filed Under: Schizophrenia, Schizophrenia Tagged With: ,

Nanoparticles loaded with bee venom kill HIV

March 12, 2013 By Leave a Comment
Anti-HIV nanoparticles

Nanoparticles (purple) carrying melittin (green) fuse with HIV (small circles with spiked outer ring), destroying the virus’s protective envelope. Molecular bumpers (small red ovals) prevent the nanoparticles from harming the body’s normal cells, which are much larger in size.
Credit: Joshua L. Hood, MD, PHD.

Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. Louis have shown. The finding is an important step toward developing a vaginal gel that may prevent the spread of HIV, the virus that causes AIDS.

“Our hope is that in places where HIV is running rampant, people could use this gel as a preventive measure to stop the initial infection,” says Joshua L. Hood, MD, PhD, a research instructor in medicine.

The study appears in the current issue of Antiviral Therapy.

Bee venom contains a potent toxin called melittin that can poke holes in the protective envelope that surrounds HIV, and other viruses. Large amounts of free melittin can cause a lot of damage. Indeed, in addition to anti-viral therapy, the paper’s senior author, Samuel A. Wickline, MD, the J. Russell Hornsby Professor of Biomedical Sciences, has shown melittin-loaded nanoparticles to be effective in killing tumor cells.

The new study shows that melittin loaded onto these nanoparticles does not harm normal cells. That’s because Hood added protective bumpers to the nanoparticle surface. When the nanoparticles come into contact with normal cells, which are much larger in size, the particles simply bounce off. HIV, on the other hand, is even smaller than the nanoparticle, so HIV fits between the bumpers and makes contact with the surface of the nanoparticle, where the bee toxin awaits.

“Melittin on the nanoparticles fuses with the viral envelope,” Hood says. “The melittin forms little pore-like attack complexes and ruptures the envelope, stripping it off the virus.”

According to Hood, an advantage of this approach is that the nanoparticle attacks an essential part of the virus’ structure. In contrast, most anti-HIV drugs inhibit the virus’s ability to replicate. But this anti-replication strategy does nothing to stop initial infection, and some strains of the virus have found ways around these drugs and reproduce anyway.

“We are attacking an inherent physical property of HIV,” Hood says. “Theoretically, there isn’t any way for the virus to adapt to that. The virus has to have a protective coat, a double-layered membrane that covers the virus.”

Beyond prevention in the form of a vaginal gel, Hood also sees potential for using nanoparticles with melittin as therapy for existing HIV infections, especially those that are drug-resistant. The nanoparticles could be injected intravenously and, in theory, would be able to clear HIV from the blood stream.

“The basic particle that we are using in these experiments was developed many years ago as an artificial blood product,” Hood says. “It didn’t work very well for delivering oxygen, but it circulates safely in the body and gives us a nice platform that we can adapt to fight different kinds of infections.”

Since melittin attacks double-layered membranes indiscriminately, this concept is not limited to HIV. Many viruses, including hepatitis B and C, rely on the same kind of protective envelope and would be vulnerable to melittin-loaded nanoparticles.

While this particular paper does not address contraception, Hood says the gel easily could be adapted to target sperm as well as HIV. But in some cases people may only want the HIV protection.

“We also are looking at this for couples where only one of the partners has HIV, and they want to have a baby,” Hood says. “These particles by themselves are actually very safe for sperm, for the same reason they are safe for vaginal cells.”

While this work was done in cells in a laboratory environment, Hood and his colleagues say the nanoparticles are easy to manufacture in large enough quantities to supply them for future clinical trials.

(news.wustl.edu. March 7, 2013)

 

Reference

Hood JL, Jallouck AP, Campbell N, Ratner L, Wickline SA. Cytolytic nanoparticles attenuate HIV-1 infectivity. Antiviral Therapy 2013; 19: 95-103.

 

Filed Under: AIDS, AIDS (videos) Tagged With: , ,

Cancer Industry Doesn’t Want A Cure

December 1, 2012 By Leave a Comment

Researchers at the University of Alberta believe dichloroacetate (DCA) may soon be used as a safe and effective treatment for many forms of cancer. DCA was once used for unusual metabolic problems. It is an odourless, colourless, inexpensive, relatively non-toxic, small molecule. However, because the compound is no longer patented, you may never see it on the market as pharmaceutical companies can’t profit from it.


 

Read More

 Relevant publications in PubMed by Dr. Michelakis

Lemmo W. DCA—my clinical experiences—intravenous and oral uses

Louis PF. Proof that the cancer industry doesn’t want a cure – even if it’s a pharmaceutical (NaturalNews, January 31, 2012)

Filed Under: Cancer, Cancer (videos) Tagged With:

Mad Child Disease (Lecture)

October 27, 2012 By Leave a Comment

Is the autism epidemic a “mad child disease” linked to mercury? This lecture was presented by Boyd Haley, Ph.D. at the 22nd Annual Meeting of the Doctors for Disaster Preparedness held in San Diego, California; June 2004.

Filed Under: Autism, Autism, Mercury, Mercury, Vaccines, Vaccines Tagged With: , , , ,

Rethinking Cancer

October 26, 2012 By Leave a Comment

Rethinking Cancer (2009) is a educational documentary film that provides a rare look into the psychological and therapeutic journeys of five men and women who used biological therapies to overcome serious illness. Their stories represent successes that mainstream medicine and the public ought to know about.

Four of the featured subjects had been diagnosed with cancer; two of these patients were considered terminal cases. The fifth patient had a severe case of Lyme disease. All five have outlived their diseases, between 15 and nearly 40 years, thus far.

Learn more at http://www.rethinkingcancer.org

Filed Under: Cancer, Cancer (videos), Nutrition, Nutrition (videos) Tagged With: ,

Pomegranates & Cancer

October 21, 2012 By Leave a Comment
Pomegranate may inhibit metastatic breast cancer(NaturalNews) Pomegranate juice is already known to be active against several cancers, but a new study out of California has just shown for the first time that it potently inhibits three key processes involved in breast cancer metastasis. The researchers were so impressed, they remarked that pomegranate juice is “potentially a very effective treatment to prevent cancer progression in general.”

Embedly Powered

via Naturalnews

Related Videos

 

References

Rocha A, Wang L, Penichet M, Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res Treat 2012, DOI: 10.1007/s10549-012-2264-5

Adhami VM, Khan N, Mukhtar H. Cancer Chemoprevention by Pomegranate: Laboratory and Clinical Evidence. Nutr Cancer. 2009 November; 61(6): 811–815.

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2012 Jun 12. doi: 10.1038/pcan.2012.20.

Jeune MA, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food 2005; 8 (4): 469-475.

Filed Under: Cancer, Cancer (videos), Pomegranate Tagged With: ,

Hannah’s Anecdote

September 8, 2012 By Leave a Comment

This is a film about Hannah Bradley who was diagnosed with an aggressive brain tumor in 2011, age 26.  Even after surgery and radiotherapy, Hannah’s future was still severely limited. Her partner Pete Cohen searched for a solution and found Dr. Stanislaw Burzynski.

Burzynski had been developing a treatment for cancer for over 40 years. Although very controversial and expensive, Hannah was accepted onto phase 2 of an FDA trial for the treatment in Texas. This is their story.

 

A film by Jamie Lowe & Pete Cohen

 

More Information

To follow Hannah’s progress and find out more about the treatment go to http://www.teamhannah.com 

 Burzynski, the Movie: Cancer Is Serious Business

Filed Under: Cancer, Cancer (videos), Disease Videos, Patient Stories Tagged With: ,

Zinc and Inflammation

August 6, 2012 By Leave a Comment

Zinc deficiency affects nearly 2 billion people in the developing world resulting in growth retardation, hypogonadism, immune dysfunction and cognitive impairment. Additionally, the roles of this divalent cation in the human body have not been clearly elucidated, since the essentiality of zinc has only been known within the last 50 years. However, it has been clearly documented that the supplementation of zinc improves many conditions such as; acute diarrhea in children, the common cold, infections in the elderly, oxidative stress and generation of inflammatory cytokines. Janet Ludwig, Ph.D. has worked in this area of study specifically modifying cellular injury by zinc supplementation.

This presentation from a webinar in May 2012 explore the following areas in order to begin to understand the therapeutic role of zinc in many inflammatory conditions:

•             Zinc roles in the body-metalloenzymes

•             Zinc as an antioxidant and anti-inflammatory agent

•             Membrane stabilization by zinc

•             Inflammatory diseases ameliorated by zinc supplementation.

 

 

Janet Ludwig, PhD

Janet Ludwig, PhD has worked in the area of zinc and inflammation for more than 25 years. She was at the Division of Surgical Biology at the Arizona Health Sciences Center studying zinc and cell injury induced by alcohol and carbon tetrachloride, an effective hepatotoxin. Additionally, she studied the mechanisms and structural identification of the potent class of inflammatory mediators, Platelet-Activating Factors (PAFs), at the Department of Pathology, University of Texas Health Sciences Center in San Antonio. She has taught courses in inflammation, biochemistry and nutrition at various Universities. She also travels to Bangkok, Thailand to give nutritional advice in a non-governmental organization that aids in improving the conditions for impoverished women and their children. Currently she is on the Hawthorn University faculty.

 

Filed Under: Inflammation, Inflammation (videos), Zinc, Zinc Tagged With: ,
Next Page »